Illustration of substances being released at a cell’s surface leading to inflammation
Illustration of substances being released at a cell’s surface leading to inflammation
Immunology
We’re an emerging leader in immunology, poised to transform medicine by rebalancing the immune responses that cause systemic, chronic diseases.
Our Immunology Pipeline
Our teams use real-world, molecular, and clinical data to advance precision medicine, and investigate:
- pathways common to systemic diseases like asthma and atopic dermatitis
- peripheral inflammatory diseases like rheumatoid arthritis
- autoimmune challenges in type 1 diabetes and cancer
Follow the Science
Taking Down Type 2 Inflammatory Disease
We’re working to tame over-active immune responses that drive systemic, chronic diseases.
From Wearables to Invisibles: Studying Sleep
Using AI and wireless tech, we’re helping people participate in research from home.
REGAINing Control of Asthma
We’re leveraging smart devices to understand the patient experience.
Type 2 Inflammation
Our goal: to give people their lives back by calming excessive inflammation–without compromising their ability to fight infection.
With our partner Regeneron, we study how blocking two interleukins1 can help calm type 2 inflammation, a driver of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and other conditions.
Beyond Type 2 Inflammation
Precision Immunology
Single-cell genomics, genetics, and proteomics help us understand exactly what makes patients different from one another.
Checkpoint Immunology
How can we restore the delicate balance between a protective immune response and destructive autoimmunity?2
Complement System
Can we stop a cascade of inflammation without compromising immunity, by blocking one protein?3
Our Latest Science Stories
October 7, 2025
How Sanofi is Rewriting the Script for Untreated Rare Diseases
More for Healthcare Professionals
Our Data-sharing Commitments
Our Disclosure Commitments
Find a Clinical Trial
Campus Sanofi
References
- Mifflin L, Ofengeim D, Yuan J (2020) Nat Rev Drug Discov 19:553-571; DOI: 10.1038/s41573-020-0071-y
- Calabrese LH, et al. (2020) J Autoimmun 115:102546; DOI: 10.1016/j.jaut.2020.102546
- Nikitin PA, et al. (2019) J Immunol 202:1200-1209; DOI: 10.4049/jimmunol.1800998